New PK/PD profile improvement following cephalosporin extended infusion : a systematic review
Abstract
Antimicrobial resistance is a global problem that is currently experienced in various countries, both developed and developing countries. The lack of discovery of new antibiotics and the increasing incidence of Multidrug–Resistant Organisms (MDROs) have sparked several efforts to optimize the administration of currently available antibiotics. Modifications in the pharmacokinetic and pharmacodynamic profiles are one of the strategies carried out, namely by extending the duration of infusion. Cephalosporins are time-dependent antibiotics; the longer they are exposed to an infusion, the more potent they are against bacteria. This is so that the drug concentration can remain above the MIC (Minimum Inhibitory Concentration) for an extended period of time throughout the infusion. In this study, articles available in Pubmed and Google Scholar from 2013-2023 using the PRISMA method related to the extension of the duration of cephalosporin infusion were evaluated. The search strategy used the keywords continuous infusion, extended infusion, prolong infusion, cefazolin, cefuroxime, ceftriaxone, ceftazidime, cefotaxime, and effectiveness. From the research results, it was found that continuous infusion was better able to achieve the desired target drug levels compared to intermittent infusion and IV bolus administration.
References
[2] J. A. Roberts et al., “Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis. A Meta-analysis of Individual Patient Data from Randomized Trials,” Am J Respir Crit Care Med, vol. 194, no. 6, pp. 681–691, Sep. 2016, doi: 10.1164/rccm.201601-0024OC.
[3] J. F. Prescott, “Beta‐lactam Antibiotics: Cephalosporins,” in Antimicrobial Therapy in Veterinary Medicine, 1st ed., S. Giguère, J. F. Prescott, and P. M. Dowling, Eds., Wiley, 2013, pp. 153–173. doi: 10.1002/9781118675014.ch9.
[4] E. Meyer, P. Gastmeier, M. Deja, and F. Schwab, “Antibiotic consumption and resistance: Data from Europe and Germany,” International Journal of Medical Microbiology, vol. 303, no. 6–7, pp. 388–395, Aug. 2013, doi: 10.1016/j.ijmm.2013.04.004.
[5] A. Lal, P. Jaoude, and A. A. El-Solh, “Prolonged versus Intermittent Infusion of β-Lactams for the Treatment of Nosocomial Pneumonia: A Meta-Analysis,” Infect Chemother, vol. 48, no. 2, p. 81, 2016, doi: 10.3947/ic.2016.48.2.81.
[6] G. Loeuille et al., “Stability Studies of 16 Antibiotics for Continuous Infusion in Intensive Care Units and for Performing Outpatient Parenteral Antimicrobial Therapy,” Antibiotics, vol. 11, no. 4, p. 458, Mar. 2022, doi: 10.3390/antibiotics11040458.
[7] J. Cousson et al., “Lung Concentrations of Ceftazidime Administered by Continuous versus Intermittent Infusion in Patients with Ventilator-Associated Pneumonia,” Antimicrob Agents Chemother, vol. 59, no. 4, pp. 1905–1909, Apr. 2015, doi: 10.1128/AAC.04232-14.
[8] B. I. Naik et al., “Comparative total and unbound pharmacokinetics of cefazolin administered by bolus versus continuous infusion in patients undergoing major surgery: a randomized controlled trial,” British Journal of Anaesthesia, vol. 118, no. 6, pp. 876–882, Jun. 2017, doi: 10.1093/bja/aex026.
[9] K. Skhirtladze‐Dworschak et al., “Cefuroxime plasma and tissue concentrations in patients undergoing elective cardiac surgery: Continuous vs bolus application. A pilot study,” British Journal of Clinical Pharmacology, 2019, doi: 10.1111/bcp.13865.
[10] H. Aardema et al., “Continuous versus intermittent infusion of cefotaxime in critically ill patients: a randomized controlled trial comparing plasma concentrations,” Journal of Antimicrobial Chemotherapy, p. dkz463, Nov. 2019, doi: 10.1093/jac/dkz463.
[11] E. Leegwater, B. V. C. Kraaijenbrink, D. J. A. R. Moes, I. M. Purmer, and E. B. Wilms, “Population pharmacokinetics of ceftriaxone administered as continuous or intermittent infusion in critically ill patients,” Journal of Antimicrobial Chemotherapy, vol. 75, no. 6, pp. 1554–1558, Jun. 2020, doi: 10.1093/jac/dkaa067.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Licencing
All articles in Jurnal Ilmu Kefarmasian Indonesia are an open-access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which permits unrestricted non-commercial used, distribution and reproduction in any medium.
This licence applies to Author(s) and Public Reader means that the users mays :
- SHARE:
copy and redistribute the article in any medium or format - ADAPT:
remix, transform, and build upon the article (eg.: to produce a new research work and, possibly, a new publication) - ALIKE:
If you remix, transform, or build upon the article, you must distribute your contributions under the same license as the original. - NO ADDITIONAL RESTRICTIONS:
You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
It does however mean that when you use it you must:
- ATTRIBUTION: You must give appropriate credit to both the Author(s) and the journal, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
You may not:
- NONCOMMERCIAL: You may not use the article for commercial purposes.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Tools
